Search results
Results from the WOW.Com Content Network
Measures to remove potassium from the body include diuretics such as furosemide, potassium-binders such as polystyrene sulfonate (Kayexalate) and sodium zirconium cyclosilicate, and hemodialysis. [1] Hemodialysis is the most effective method. [3] Hyperkalemia is rare among those who are otherwise healthy. [6]
Potassium binders are medications that bind potassium ions in the gastrointestinal tract, thereby preventing its intestinal absorption. This category formerly consisted solely of polystyrene sulfonate, a polyanionic resin attached to a cation, administered either orally or by retention enema to patients who are at risk of developing hyperkalaemia (abnormal high serum potassium levels).
Polystyrene sulfonate is usually supplied in either the sodium or calcium form. It is used as a potassium binder in acute and chronic kidney disease for people with hyperkalemia (an abnormally high blood serum potassium level). [ 3 ]
Several approaches are used to treat hyperkalemia. [12] Other approved potassium binders in the United States include patiromer and sodium polystyrene sulfonate. [13] Hyperkalemia, particularly if severe, is a marker for an increased risk of death. [14] However, there is disagreement regarding whether a modestly elevated levels directly causes ...
Definitive treatment of hyperkalemia requires actual excretion of potassium, either through urine (which can be facilitated by administration of loop diuretics such as furosemide) or in the stool (which is accomplished by giving sodium polystyrene sulfonate enterally, where it will bind potassium in the GI tract.)
Sodium polyanethol sulfonate (anticoagulant) and growth media for microorganisms: Usually drawn first for minimal risk of contamination. [1] Two bottles are typically collected in one blood draw; one for aerobic organisms and one for anaerobic organisms. [2] Blue ("light blue") Sodium citrate (weak calcium chelator/anticoagulant)
U.S. regulators have recommended pausing the use of Johnson & Johnson's COVID-19 vaccine, as they investigate rare blood clotting in six women. J&J also said it was stopping the rollout of its ...
The tubes have micronized silica particles which help clot the blood before centrifugation, and a gel at the bottom which separates whole blood cells from serum. [1] Silica nanoparticles induce coagulation through contact activation of coagulation factor XII (Hageman factor). [ 2 ]